At the time of writing, Iovance Biotherapeutics Inc [IOVA] stock is trading at $2.64, up 2.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IOVA shares have gain 2.72% over the last week, with a monthly amount glided 32.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on July 15, 2025, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $1 for it. Previously, UBS downgraded its rating to Neutral on May 16, 2025, and kept the price target unchanged to $2. On May 12, 2025, downgrade downgraded it’s rating to Hold. Citizens JMP downgraded its rating to a Mkt Perform. UBS initiated its recommendation with a Buy and recommended $17 as its price target on October 24, 2024. Piper Sandler downgraded its rating to Neutral for this stock on July 29, 2024, and downed its price target to $10. In a note dated November 20, 2023, Goldman initiated an Buy rating and provided a target price of $12 on this stock.
For the past year, the stock price of Iovance Biotherapeutics Inc fluctuated between $1.64 and $12.51. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $2.64 at the most recent close of the market. An investor can expect a potential return of 51.52% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
According to Iovance Biotherapeutics Inc [NASDAQ:IOVA], the company’s sales were 212.68M for trailing twelve months, which represents an 6798.46% jump. Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -1.88%, Pretax Profit Margin comes in at -1.78%, and Net Profit Margin reading is -1.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.5 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Iovance Biotherapeutics Inc [NASDAQ:IOVA] has a current ratio of 4.18. As well, the Quick Ratio is 3.64, while the Cash Ratio is 1.4. Considering the valuation of this stock, the price to sales ratio is 4.15, the price to book ratio is 1.15.
Transactions by insiders
Recent insider trading involved Kirby Daniel Gordon, Chief Commercial Officer, that happened on Jun 05 ’25 when 30000.0 shares were purchased. Chief Regulatory Officer, Puri Raj K. completed a deal on May 23 ’25 to buy 5600.0 shares. Meanwhile, Interim CEO & General Counsel Vogt Frederick G bought 25000.0 shares on May 14 ’25.
